Cevimeline
From Wikipedia, the free encyclopedia
| Image:Cevimeline.png | |
|
Cevimeline
|
|
| Systematic (IUPAC) name | |
| 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C10H17NOS |
| Mol. mass | 489.565 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | < 20% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
[edit] Mechanism of action
By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.
[edit] See also
[edit] External links
- Evoxac - Manufacturer's home page
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
